8-K: PepGen Inc. Updates on DM1 Therapy PGN-EDODM1

PepGen Inc. provided an update on its investigational therapy PGN-EDODM1 for Myotonic Dystrophy Type 1, highlighting promising safety and efficacy data from its FREEDOM studies.

Summary

• PepGen Inc. presented an update on its corporate presentation regarding PGN-EDODM1, an investigational therapy for Myotonic Dystrophy Type 1 (DM1).
• The presentation detailed the company's EDO platform, designed to improve oligonucleotide delivery to cell nuclei.
• Data from the FREEDOM SAD study showed dose-dependent splicing correction, with the 15 mg/kg dose achieving significant improvements.
• The FREEDOM2 MAD study at the 5 mg/kg dose demonstrated a generally well-tolerated safety profile with mild to moderate adverse events and promising trends in functional assessments (vHOT).
• The company reported a mean splicing correction of 7.3% in the 5 mg/kg MAD cohort, which increased to 22.9% when excluding a notable outlier.
• PepGen has strong cash runway into the second half of 2027, covering the FREEDOM2 12.5 mg/kg MAD readout.
• Upcoming milestones include FREEDOM2 10 mg/kg clinical results in 2H 2026 and FREEDOM2 12.5 mg/kg clinical results in 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, with promising preclinical and early clinical data for PGN-EDODM1, offset by a partial FDA clinical hold and the inherent risks of drug development.

Positives

• PGN-EDODM1 demonstrated dose-dependent splicing correction in the FREEDOM SAD study, with the 15 mg/kg dose showing significant results.
• The EDO platform shows potential for improved endosomal escape and up to 98-fold increase in nuclear uptake of oligonucleotides.
• PGN-EDODM1 has received Orphan Drug & Fast Track Designation in the U.S. and Orphan Designation in the EU.
• The FREEDOM2 MAD study at 5 mg/kg showed a generally well-tolerated safety profile with all adverse events being mild or moderate.
• No serious adverse events (SAEs), adverse events of special interest (AESIs), or dose-limiting toxicities (DLTs) were observed in the 5 mg/kg MAD cohort.
• Promising trends in video hand opening test (vHOT) were observed in the PGN-EDODM1 treated group in the FREEDOM2 5 mg/kg MAD cohort.
• Strong cash runway is projected into the second half of 2027, extending through the FREEDOM2 12.5 mg/kg MAD readout.

Negatives

• The U.S. FDA placed a partial clinical hold on the FREEDOM2 study.
• A transient decrease in eGFR(cys) and transient albuminuria were observed at the 15 mg/kg dose in the FREEDOM SAD study.
• One drug-related SAE of severe abdominal pain occurred at 10 mg/kg in the FREEDOM SAD study, confounded by off-label medication use.
• One drug-related hypersensitivity reaction (rash) occurred during infusion at 15 mg/kg in the FREEDOM SAD study.
• The mean splicing correction in the FREEDOM2 5 mg/kg MAD cohort was 7.3%, with a notable outlier impacting the average.
• The 5 mg/kg MAD cohort in FREEDOM2 showed a mean vHOT change of -2.95 seconds, indicating a trend below baseline.

Risks

• Delays or failure to successfully initiate or complete ongoing and planned development activities for PGN-EDODM1.
• Inability to enroll patients in clinical trials, including FREEDOM2.
• Clinical and preclinical study results interpretation may be incorrect, or anticipated therapeutic activity may not be observed.
• PGN-EDODM1 may not be safe and effective or demonstrate safety and efficacy in clinical trials.
• Adverse regulatory interactions, including delays in review, clearance to proceed, or approval by regulatory authorities.
• The FDA's partial clinical hold on the FREEDOM2 study could lead to modifications or delays in development programs.
• Challenges in obtaining, maintaining, and protecting intellectual property, and defending patent portfolios.
• Competition from other companies developing therapies for DM1.
• Unexpected increases in development expenses or events adversely impacting financial resources and cash runway.
• Dependence on third parties for manufacturing, research, and testing.

Future Outlook

PepGen anticipates reporting clinical data from the FREEDOM2 10 mg/kg multiple dose cohort in the second half of 2026 and from the FREEDOM2 12.5 mg/kg cohort in 2027. The company projects a strong cash runway into the second half of 2027, sufficient to cover the FREEDOM2 12.5 mg/kg MAD readout.

Management Comments

• The company aims to develop therapies that address the root cause of serious genetic neuromuscular and neurological diseases, driving meaningful, functional improvement.
• PGN-EDODM1 is designed to selectively target only pathogenic DMPK RNA, with a favorable emerging safety profile.
• The company is on track to report clinical data from the 10 mg/kg multiple dose cohort in 2H 2026.

Industry Context

StockSavvy.ai notes that PepGen's update positions PGN-EDODM1 as a potential best-in-class therapy for DM1, leveraging its proprietary EDO platform to overcome oligonucleotide delivery challenges. The company's progress aligns with the broader industry trend of developing targeted genetic therapies for rare diseases, though competition and regulatory hurdles remain significant.

Stakeholder Impact

• Shareholders: Potential for future value creation if PGN-EDODM1 proves successful, but also risks associated with clinical trial outcomes and regulatory approvals.
• Patients with DM1: Hope for a potential new therapy that addresses the underlying cause of their disease, with ongoing clinical trials offering potential functional improvements.
• Healthcare Providers: Information on a novel therapeutic approach and its emerging safety and efficacy profile for DM1 management.

Next Steps

• Report FREEDOM2 10 mg/kg clinical results in 2H 2026.
• Report FREEDOM2 12.5 mg/kg clinical results in 2027.
• Continue development of the EDO platform for other genetic conditions.
• Engage in ongoing and planned regulatory interactions.

Key Dates

Recommendation

The update provides encouraging early-stage data for PGN-EDODM1, particularly regarding splicing correction and safety. However, the FDA's partial clinical hold on FREEDOM2 and the inherent uncertainties in late-stage drug development warrant a cautious 'hold' recommendation pending further data readouts and resolution of regulatory issues.

Keywords

PepGen, PGN-EDODM1, Myotonic Dystrophy Type 1, DM1, EDO Platform, Clinical Trials, Gene Therapy, Oligonucleotides